Agreement - October 27, 2016
Brighter merges the jDome business with Bestic
Via its subsidiary, Brighter Two AB, Brighter acquired Bestic, a Swedish robotics company that develops and sells products and assistive devices for the healthcare and nursing sector. In conjunction with the acquisition, Brighter Two, which develops and sells jDome BikeAround, is merged with Bestic. Brighter Two is also changing its name to Camanio Care AB […]
Agreement - October 24, 2016
NeuroVive and Arbutus sign termination agreement
NeuroVive Pharmaceutical has announced that the license agreement with Arbutus Biopharma (formerly OnCore Biopharma) has been terminated and all rights to the NVP018 compound have been reverted back to NeuroVive. The agreement, signed in 2014, was related to the development and commercialization of NeuroVive’s compound NVP018 for oral treatment of Hepatitis B viral infection. In its […]
Agreement - October 19, 2016
BC Platforms, Karolinska extend partnership
BC Platforms announced that the Center for Molecular Medicine (CMM) at the Karolinska Institute has extended its research partnership with them to encompass its newest version of the platform and include its BC|GENOME and BC|TILING tools to add capacity for large scale next generation sequencing as well as superior data handling and analytics. Ingrid Kochum, […]
Agreement - October 10, 2016
Nordic Nanovector in new collaboration
Nordic Nanovector has entered into a collaboration with LegoChem Biosciences, a South Korea-based biopharmaceutical company, to develop novel CD37-targeting antibody-drug conjugates (ADCs) for the treatment of leukaemias. Leukemias are orphan diseases with a significant unmet medical need, representing a growing market estimated to be worth over USD 5 billion by 2024. This collaboration supports Nordic […]
Agreement - October 3, 2016
AstraZeneca in agreement with Allergan
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan plc for the global rights to MEDI2070. MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease (a chronic inflammatory disease of the intestines) and is ready for […]
Agreement - September 13, 2016
Glooko and Diasend merge
Glooko and Diasend have merged into a unified company. Glooko and Diasend offers diabetes management and analytics platforms that facilitate data driven care for patients and clinicians. “This is a big day for us – we are thrilled to come together to be able to deliver products and services that will offer even more value to patients […]
